Latest From Curis Inc.
Public Company Edition: COO Dean Hum talked to Scrip about Genfit's IPO strategy – which wasn't just about raising money – as it anticipates Phase III elafibranor data later this year. Also, Precision BioSciences launches its IPO, while Myokardia, Dermira and Tricida lead new public company financings.
Industry executives, consultants and analysts speculate on what they believe the big themes, trends and events will be this year.
Scrip journalists asked industry executives, consultants and analysts what they believe the big themes, trends and events will be in 2019. Here's what they told us about advances in therapeutic technologies and areas of clinical innovation.
Appointments: BMS CCO Leaves, New Medical Heads At Astellas Americas, Epizyme, CEOs At NanoViricides, Aeglea, Waverley Pharma
Bristol-Myers Squibb's CCO Murdo Gordon has exited the company in the week of its Q2 results, while Trevi Therapeutics, Turnstone Biologics, Aeglea BioTherapeutics, Acadia Pharmaceuticals, NanoViricides and Waverley Pharmaceuticals add to their C-suite. Medical heads join Epizyme and Astellas Americas.
- Therapeutic Areas
- Creative BioMolecules Inc.
- Ontogeny Inc.
- Reprogenesis Inc.
- North America
- Parent & Subsidiaries
- Curis Inc.
- Senior Management
James E Dentzer, Pres. & CEO
Robert Martell, MD, PhD, Head, R&D
- Contact Info
Phone: (617) 503-6500
4 Maguire Rd.
Lexington, MA 02421
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.